Business Wire

OR-POWIN

Share
Powin Unveils Next-Generation Pod Platform at CLEANPOWER 2024

Global energy storage platform provider Powin LLC (Powin) today announced its new multi-cell-based hardware platform, the Powin Pod (Pod). Designed for utility-scale projects, Pod takes Powin’s battery energy storage system (BESS) technology to the next level, setting a new standard for energy storage solutions with higher energy density, top-tier safety, reliability and enhanced cost savings. The Pod platform complements Powin's Centipede product line, offering a comprehensive suite of solutions to meet diverse customer requirements.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507995695/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Powin's new multi-cell-based hardware platform, the Powin Pod. (Photo: Business Wire)

"We consistently challenge ourselves to improve our products and services to ensure we are continuously delivering nothing short of excellence to both new and existing customers," said Jeff Waters, CEO of Powin. "This next-generation product advancement demonstrates our commitment to bringing the safest and highest quality energy storage solutions to the market, advancing the entire industry as a result."

The new Pod platform is part of a fully integrated Powin energy storage solution that includes an end-to-end offering—spanning StackOS software, system design, delivery, commissioning and long-term service—that will enable Powin to meet growing customer needs with an improved, reliable and energy-dense storage platform. Powin’s proprietary Battery Management System and Energy Management controls comply with robust localized cybersecurity standards and regulations, ensuring superior protection for data privacy and intellectual property, guaranteeing security of customers’ data, operations and investment at all times. Customers who select Pod will benefit from Powin's full authorization to perform long-term services at their site, as well as comprehensive system training from the company. Within a fully integrated solution, Powin delivers safety, availability, insight and flexibility, providing lower risk, enhanced performance and improved revenue generation.

The Powin Pod platform offers benefits such as:

  • Higher-density energy storage: Upgraded cell capacity, utilization of cell-to-pack technology and optimized internal space maximizes energy density and results in significant land savings for projects. Powin Pod delivers a 50% increase in energy density from the Powin Centipede platform. This solution and density improvement is available at 2-hour or greater system applications.
  • Top-tier safety and reliability: Liquid cooling provides more stable internal battery system temperatures, ensuring enhanced system safety and longevity. Powin complies with the latest and most stringent fire prevention standards such as UL9540A, NFPA 68 and NFPA 69, while having optional class-leading fire suppression at module and container level.
  • Enhanced cost savings: Powin Pod’s compact size reduces the amount of land required for installation, and Powin’s faster and lower cost shipping and on-time delivery combined with simplified installation and commissioning processes allow for lower CAPEX and greater customer savings.

With a proven track record of over 17 GWh deployed and under construction worldwide and over six million battery cells monitored, Powin is a trusted and established US-based integrator. Powin provides world-class logistics for on-time delivery, 20-year performance guarantee and long-term service structures and relies on a 24/7 Remote Operations Center and over 500 field service technicians and Authorized Service Providers to ensure optimal system performance.

Powin Pod is now available to order in markets globally and delivery is expected to begin in mid-2025. Starting in 2026, Powin Pod will be manufactured in the US complying with US Domestic Content requirements. To learn more about Powin’s latest product advancements, please visit https://powin.com/powin-pod/ or visit the Powin team at CLEANPOWER 2024 at booth #2645.

About Powin, LLC (Powin)

At Powin, we are advancing the next frontier of energy and changing the way we power our daily lives by ensuring access to clean, resilient, and affordable power. As a global energy storage platform provider, we offer fully integrated battery solutions, software, and services to optimize grid performance and enable the transition to cleaner energy sources. To learn more, please visit www.powin.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240507995695/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye